Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

BOTHELL, Wash., Aug. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex: DDD) today reported financial results for the three and six months ended June 30, 2009.

Dr. Bruce Morra, SCOLR Pharma's President and CEO, said, "We continue to advance discussions with a number of potential partners for our 12-hour controlled release ibuprofen. These potential partners have been committing resources to due diligence and preliminary negotiations of license terms. In the nutraceutical arena, we are working with companies interested in commercializing products we have developed for growing segments of this field in both the US and international markets. We continue to work with our investment bankers on potential strategic transactions, including mergers and other business combinations that could yield opportunities to increase shareholder value and provide additional resources for us to develop our Controlled Delivery Technology (CDT(R)) platforms. However, we are faced with a difficult marketplace and many specialty pharmaceutical companies competing for alliances with the more established pharmaceutical and consumer product companies. Our operating strategy is to preserve our capital by limiting clinical and development expenses to our ibuprofen and pseudoephedrine lead products while also supporting our existing alliances. We have made significant reductions to our operating expenses so far this year and are continuing to evaluate additional areas to further minimize our burn rate."

Total revenues, which consist of royalty revenue from our collaboration agreements, decreased 17%, or $48,782 to $230,789 for the three months ended June 30, 2009, compared to $279,571 for the same period in 2008. This decrease is primarily due to lower royalty income from our relationship with Perrigo.

Royalt
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... , July 10, 2014 Research and ... of the "International Photonic Integrated Circuit (Monolithic ... to 2019" report to their offering. ... The concept of photonic integration traces its roots ... The promise of photonic integration went unexplored and ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... announced that yesterday, the highest court of ... in a precedent-setting,decision the validity of one ... inventions. As Lord Neuberger of Abbotsbury, commented,"The ...
... Demonstrates Strong Commitment to Ethical Information Exchange between ... ... -, ROCKLAND, Mass., July 10 EMD Serono, Inc. ... the revised,and strengthened PhRMA Code on Interactions with Healthcare Professionals.,The ...
... ANNAPOLIS, Md., July 10 PharmAthene, Inc.,(Amex: ... development and,commercialization of medical countermeasures against chemical and,biological ... has been,appointed Senior Vice President & General Counsel, ... Mr. Karp joins PharmAthene with over 17 ...
Cached Biology Technology:Angiotech wins before the UK House of Lords 2Angiotech wins before the UK House of Lords 3Angiotech wins before the UK House of Lords 4EMD Serono to Adopt Revised and Strengthened PhRMA Code 2EMD Serono to Adopt Revised and Strengthened PhRMA Code 3EMD Serono to Adopt Revised and Strengthened PhRMA Code 4PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel 2PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel 3
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... According to the new market ... Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application ... & Finance), and Geography - Global Trends & Forecasts ... Fingerprint Sensors Market is projected to cross $14.35 Billion ... from 2014 to 2020. Browse more than ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch ... A Chinese Top 5 smartphone OEM has selected FPC1021 for ... in October 2014.   FPC is proud to ... which has a planned date for the start of mass ... this phone of 3 million units. The Chinese OEM wants ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... people with HIV from also becoming infected with hepatitis, researchers ... Behaviors that put people at higher risk of contracting ... transfusions, for instance also raise their risk of getting ... if untreated, can be deadly. The study, which included ...
... NY. (March. 27, 2013) A team ... can improve the neurobehavioral function of six ... cells (ASCs) to treat hypoxic-ischemic brain injury, and ... some animals through exercise-induced fibroblast growth factor 2 ...
... 26, 2013 Like it or not and despite the ... jour for movie-making in Hollywood. It now turns out that ... According to a new study published in Biological Psychiatry ... systems: one system that directs attention to affective states ("I ...
Cached Biology News:HIV sufferers need hepatitis safeguards 2Environmental enrichment important factor impacting cell transplantation and brain repair 2Environmental enrichment important factor impacting cell transplantation and brain repair 3Human emotion: We report our feelings in 3-D 2
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: